102 related articles for article (PubMed ID: 26486738)
1. Development and validation of CALR mutation testing for clinical diagnosis.
Maier CL; Fisher KE; Jones HH; Hill CE; Mann KP; Zhang L
Am J Clin Pathol; 2015 Nov; 144(5):738-45. PubMed ID: 26486738
[TBL] [Abstract][Full Text] [Related]
2. Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms.
Mehrotra M; Luthra R; Singh RR; Barkoh BA; Galbincea J; Mehta P; Goswami RS; Jabbar KJ; Loghavi S; Medeiros LJ; Verstovsek S; Patel KP
Am J Clin Pathol; 2015 Nov; 144(5):746-55. PubMed ID: 26486739
[TBL] [Abstract][Full Text] [Related]
3. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM
Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326
[TBL] [Abstract][Full Text] [Related]
4. Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis.
Jeong JH; Lee HT; Seo JY; Seo YH; Kim KH; Kim MJ; Lee JH; Park J; Hong JS; Park PW; Ahn JY
Ann Lab Med; 2016 Jul; 36(4):291-9. PubMed ID: 27139600
[TBL] [Abstract][Full Text] [Related]
5. [Allele-specific polymerase chain reaction and electrophoretic detection in the detection algorithm clinically significant somatic mutations in the gene of calreticulin (calr).].
Gorbenko AS; Stolyar MA; Olkhovskiy IA; Abdullaev AO; Sudarikov AB; Dunaeva EA; Mironov KO; Shipulin GA
Klin Lab Diagn; 2018; 63(9):588-592. PubMed ID: 30735328
[TBL] [Abstract][Full Text] [Related]
6. Pyrosequencing-based quantitative measurement of CALR mutation allele burdens and their clinical implications in patients with myeloproliferative neoplasms.
Oh Y; Song IC; Kim J; Kwon GC; Koo SH; Kim SY
Clin Chim Acta; 2018 Aug; 483():183-191. PubMed ID: 29727699
[TBL] [Abstract][Full Text] [Related]
7. Calreticulin Mutations in Myeloproliferative Neoplasms: Comparison of Three Diagnostic Methods.
Park JH; Sevin M; Ramla S; Truffot A; Verrier T; Bouchot D; Courtois M; Bas M; Benali S; Bailly F; Favre B; Guy J; Martin L; Maynadié M; Carillo S; Girodon F
PLoS One; 2015; 10(10):e0141010. PubMed ID: 26501981
[TBL] [Abstract][Full Text] [Related]
8. Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms.
Andrici J; Farzin M; Clarkson A; Sioson L; Sheen A; Watson N; Toon CW; Koleth M; Stevenson W; Gill AJ
Pathology; 2016 Jun; 48(4):319-24. PubMed ID: 27114372
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
10. Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring.
Chi J; Manoloukos M; Pierides C; Nicolaidou V; Nicolaou K; Kleopa M; Vassiliou G; Costeas P
Ann Hematol; 2015 Mar; 94(3):399-408. PubMed ID: 25349114
[TBL] [Abstract][Full Text] [Related]
11. A novel molecular assay using hybridisation probes and melt curve analysis for
Keaney T; O'Connor L; Krawczyk J; Abdelrahman MA; Hayat AH; Murray M; O'Dwyer M; Percy M; Langabeer S; Haslam K; Glynn B; Mullen C; Keady E; Lahiff S; Smith TJ
J Clin Pathol; 2017 Aug; 70(8):662-668. PubMed ID: 28143941
[TBL] [Abstract][Full Text] [Related]
12. CALR mutation profile in Irish patients with myeloproliferative neoplasms.
Haslam K; Conneally E; Flynn CM; Cahill MR; Gilligan O; O'Shea D; Langabeer SE
Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):112-5. PubMed ID: 27352261
[TBL] [Abstract][Full Text] [Related]
13. Conformation sensitive gel electrophoresis for the detection of calreticulin mutations in BCR-ABL1-negative myeloproliferative neoplasms.
Zakaria NA; Rosle NA; Siti Asmaa MJ; Aziee S; Haiyuni MY; Samat NA; Husin A; Hassan R; Ramli M; Mohamed Yusoff S; Ibrahim IK; Al-Jamal HAN; Johan MF
Int J Lab Hematol; 2021 Dec; 43(6):1451-1457. PubMed ID: 34125992
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms.
Jones AV; Ward D; Lyon M; Leung W; Callaway A; Chase A; Dent CL; White HE; Drexler HG; Nangalia J; Mattocks C; Cross NC
Leuk Res; 2015 Jan; 39(1):82-7. PubMed ID: 25499808
[TBL] [Abstract][Full Text] [Related]
15. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
16. Rapid and sensitive detection of calreticulin type 1 and 2 mutations by real-time quantitative PCR.
Zinke M; Nageswaran V; Reinhardt R; Burmeister T
Mol Diagn Ther; 2015 Oct; 19(5):329-34. PubMed ID: 26294037
[TBL] [Abstract][Full Text] [Related]
17. A novel assay to detect calreticulin mutations in myeloproliferative neoplasms.
Rosso V; Petiti J; Bracco E; Pedrola R; Carnuccio F; Signorino E; Carturan S; Calabrese C; Bot-Sartor G; Ronconi M; Serra A; Saglio G; Frassoni F; Cilloni D
Oncotarget; 2017 Jan; 8(4):6399-6405. PubMed ID: 28031530
[TBL] [Abstract][Full Text] [Related]
18. RAPID LOW-COST DETECTION OF TYPE 2CALR MUTATION BY ALLELE-SPECIFIC RT-PCR FOR DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS.
Dybkov MV; Zavelevich MP; Gluzman DF; Telegeev GD
Exp Oncol; 2022 May; 44(1):83-86. PubMed ID: 35548965
[TBL] [Abstract][Full Text] [Related]
19. Droplet digital PCR assay for quantifying of CALR mutant allelic burden in myeloproliferative neoplasms.
Anelli L; Zagaria A; Coccaro N; Tota G; Minervini A; Casieri P; Impera L; Minervini CF; Brunetti C; Ricco A; Orsini P; Cumbo C; Specchia G; Albano F
Ann Hematol; 2016 Sep; 95(9):1559-60. PubMed ID: 27365140
[No Abstract] [Full Text] [Related]
20. Pitfalls in CALR exon 9 mutation detection: A single-center experience in 571 positive patients.
Verger E; Maslah N; Schlageter MH; Chomienne C; Kiladjian JJ; Giraudier S; Cassinat B
Int J Lab Hematol; 2020 Dec; 42(6):827-832. PubMed ID: 32614523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
